Genta Incorporated (OTCBB: GNTA) announced that the Company will host a
conference call and live audio webcast of its 2008 Annual Meeting of
Shareholders. The meeting will be held on Monday, October 6, 2008 at
11:00 a.m., EDT at the Company’s headquarters
located at 200 Connell Drive, Berkeley Heights, NJ 07922. The
presentation will include an overview of the Company's key programs and
strategies by senior management.
Conference call and webcast information:
Audio replay will be available approximately two hours after the
completion of the call, and will be archived for 30 days. Access numbers
for this replay are: (800) 642-1687 (U.S./Canada) and (706) 645-9291
(International); conference ID number is: 64394129. Shareholders wishing
to attend the meeting may obtain directions by visiting the Genta
website at www.genta.com.
About Genta
Genta Incorporated is a biopharmaceutical company with a diversified
product portfolio that is focused on delivering innovative products for
the treatment of patients with cancer. Two major programs anchor the
Company’s research platform: DNA/RNA-based
Medicines and Small Molecules. Genasense®
(oblimersen sodium) Injection is the Company's lead compound from its
DNA/RNA Medicines program. Genta is currently recruiting patients to the
AGENDA Trial, a global Phase 3 trial of Genasense in patients with
advanced melanoma. The leading drug in Genta’s
Small Molecule program is Ganite® (gallium
nitrate injection), which the Company is exclusively marketing in the
U.S. for treatment of symptomatic patients with cancer-related
hypercalcemia that is resistant to hydration. The Company has developed
G4544, an oral formulation of the active ingredient in Ganite, that has
recently entered clinical trials as a potential treatment for diseases
associated with accelerated bone loss. The Company is also developing
tesetaxel, a novel, orally absorbed, semi-synthetic taxane that is in
the same class of drug as paclitaxel and docetaxel. Ganite and Genasense
are available on a "named-patient”
basis in countries outside the United States. For more information about
Genta, please visit our website at: www.genta.com.
SAFE HARBOR
This press release may contain forward-looking statements with
respect to business conducted by Genta Incorporated. By their nature,
forward-looking statements and forecasts involve risks and uncertainties
because they relate to events and depend on circumstances that will
occur in the future.
Forward-looking statements include, without
limitation, statements about:
-
the Company’s ability to obtain necessary
regulatory approval for Genasense®
from the U.S. Food and Drug Administration ("FDA”)
or European Medicines Agency ("EMEA”);
-
the safety and efficacy of the Company’s
products or product candidates;
-
the Company’s assessment of its clinical
trials;
-
the commencement and completion of clinical trials;
-
the Company’s ability to develop,
manufacture, license and sell its products or product candidates;
-
the Company’s ability to enter into and
successfully execute license and collaborative agreements, if any;
-
the adequacy of the Company’s capital
resources and cash flow projections, the Company’s
ability to obtain sufficient financing to maintain the Company’s
planned operations, or the Company’s risk
of bankruptcy if it is unsuccessful in obtaining such financing or in
securing shareholder approval to increase the number of shares
authorized for issuance under the Company’s
certificate of incorporation, as required by the transactional
documents in our recent financing;
-
the adequacy of the Company’s patents
and proprietary rights;
-
the impact of litigation that has been brought against the Company
and its officers and directors and any proposed settlement of such
litigation; and
-
the other risks described under Certain Risks and Uncertainties
Related to the Company’s Business, as
contained in the Company’s Annual Report on
Form 10-K and Quarterly Report on Form 10-Q.
The Company does not undertake to update any forward-looking
statements.
There are a number of factors that could cause actual
results and developments to differ materially.
For a discussion
of those risks and uncertainties, please see the Company's Annual Report
on Form 10-K for 2007 and its most recent quarterly report on Form 10-Q.
